The next-generation CoreValve Evolut PRO got FDA approval for high-risk patients undergoing transcatheter aortic valve replacement, according to an announcement by Medtronic. At last week's American College of Cardiology meeting in Washington, D.C., researchers unveiled a relatively low 11.8% pacemaker rate at 30 days with the device. (MedPage Today)